Hemostemix Inc. (CVE:HEM – Get Free Report) Director Peter Alan Lacey bought 200,000 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of C$0.15 per share, with a total value of C$30,000.00.
Peter Alan Lacey also recently made the following trade(s):
- On Wednesday, February 26th, Peter Alan Lacey sold 96,464 shares of Hemostemix stock. The stock was sold at an average price of C$0.18, for a total value of C$16,881.20.
Hemostemix Stock Performance
CVE:HEM opened at C$0.12 on Thursday. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. Hemostemix Inc. has a 12-month low of C$0.04 and a 12-month high of C$0.43. The stock has a 50-day moving average price of C$0.22 and a 200 day moving average price of C$0.13. The stock has a market capitalization of C$17.49 million, a P/E ratio of -3.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- With Risk Tolerance, One Size Does Not Fit All
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Dividend Payout Ratio Calculator
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Want to Profit on the Downtrend? Downtrends, Explained.
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
